1Prenzel N, Fischer OM, Streit S, et al. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification [J]. Endocrine-Relate Cancer,2001,8 : 11.
2Nyati MK,Morgan MA, Feng FY, et al. Integration of EGFR inhibitors with Radiochemotherapy[J].Nat Ca Rev,2006,6 : 876.
4Vallbohmer D,Zhang W, Gordon M, et al. Molecular determinants of cetuximab efficacy [J].Clin Oncol, 2005,23 : 3536.
5Caponigro F. Rationale and clinical validation of epidermal growth factor receptor as a target in the treatment of head and neck cancer [J].Anti-Cancer Drugs,2004,15:311.
6Akimoto T, Hunter N, Milas L,et al. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas [J]. Clinical Cancer Research, 1999,5:2884.
7Bentzen SM,Bernier J. Radiotherapy for head and neck cancer: latest developments and future perspectives [ J].Current Opinion in Oncology, 2006,18 : 240.
8Fountzilas G, Ciuleanu E,Dafni U,et al. Concomitant radiochemotherapy vs radiotherapy alone in patient s wit h head and neck cancer : a Hellenic Cooperative Oncology Group Phase Ⅲ Study [J].Med Oncol,2004,21 (2) :95.
9Specenier P, Vermorken JB. The role of taxanes and targeted therapies in locally advanced head and neck cancer [J].Curr Opin Oncol, 2007,19 : 195.
10Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus Cetuximab forsquamous cell carcinoma of the head and neck [J].N Engl J Med, 2006,354 (6) : 567.
2Giantonio BJ,Catalano PJ,Meropol NJ,et al.High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer:Results from the Eastern Cooperative Oncology Group (ECOG) study E3200[ J].Pro Am Soc Clin Oncol,2005,23:1s Abstr 2.
3Sandler AB,Gray R,Brahmer J,et al.Randomized phase Ⅱ/Ⅲ trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC):An Eastern Cooperative Oncology Group (ECOG) trial-E4599 [ J].Pro Am Soc Clin Oncol,2005,23:2s LBA4.
4Half E,Broaddus R,Danenberg KD,et al.HER-2 receptor expression,localization,and activation in colorectal cancer cell lines and human tumors [ J ].Int J Cancer,2004,108:540-548.
5Sekharam M,Zhao H,Sun M,et al.Insulin-like growth factor 1receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt/Bcl-x(L) pathway[J].Cancer Res,2003,63:7708-7716.
6Chun YJ,Park S,Yang SA,et al.Activation of Fas receptor modulates cytochrome P450 3A4 expression in human colon carcinoma cells[ J].Toxicol Lett,2003,146:75-81.
7Ohana G,Bar-Yehuda S,Arich A,et al.Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist CF101 [ J].Br J Cancer,2003,89:1552-1558.
8Hainsworth JD,Sosman JA,Spigel DR,et al.Phase Ⅱ trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma(RCC) [ J].Proc Am Soc Clin Onco1,2004,22:382s(abstr 4502).
9Motzer RJ,Rini BI,Michaelson MD,et al.SU0 11248,a novel tyrosine kinase inhibitor,shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma:results of a phase 2 trial[J].Proc Am Soc Clin 0ncol,2004,22:382s (abstr 4500).
10Drach J,Kaufmann H,Woehrer S,et al.Durable remissions after rituximab plus thalidomide for relapsed/refractory mantle cell lymphoma[ J].Proc Am Soc Clin Oncol,2004,22:578s (abstr 6583).
